275 related articles for article (PubMed ID: 30288546)
1. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
J Mol Med (Berl); 2018 Dec; 96(12):1307-1318. PubMed ID: 30288546
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway.
Hsu FS; Wu JT; Lin JY; Yang SP; Kuo KL; Lin WC; Shi CS; Chow PM; Liao SM; Pan CI; Hong JY; Chang HC; Huang KH
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866433
[TBL] [Abstract][Full Text] [Related]
3. Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells.
Jeon HG; Yoon CY; Yu JH; Park MJ; Lee JE; Jeong SJ; Hong SK; Byun SS; Lee SE
J Urol; 2011 Nov; 186(5):2084-93. PubMed ID: 21944112
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor trichostatin A resensitizes gemcitabine resistant urothelial carcinoma cells via suppression of TG-interacting factor.
Yeh BW; Li WM; Li CC; Kang WY; Huang CN; Hour TC; Liu ZM; Wu WJ; Huang HS
Toxicol Appl Pharmacol; 2016 Jan; 290():98-106. PubMed ID: 26589485
[TBL] [Abstract][Full Text] [Related]
5. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
[TBL] [Abstract][Full Text] [Related]
6. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z
PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799
[TBL] [Abstract][Full Text] [Related]
7. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.
Duo J; Ma Y; Wang G; Han X; Zhang C
DNA Cell Biol; 2013 Apr; 32(4):156-64. PubMed ID: 23451817
[TBL] [Abstract][Full Text] [Related]
8. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406
[TBL] [Abstract][Full Text] [Related]
9. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Mazzio EA; Soliman KFA
Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076
[TBL] [Abstract][Full Text] [Related]
10. Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models.
Sakamoto T; Ozaki K; Fujio K; Kajikawa SH; Uesato S; Watanabe K; Tanimura S; Koji T; Kohno M
Biochem Biophys Res Commun; 2013 Apr; 433(4):456-62. PubMed ID: 23501104
[TBL] [Abstract][Full Text] [Related]
11. Correction to: Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
J Mol Med (Berl); 2019 Mar; 97(3):435-436. PubMed ID: 30741319
[TBL] [Abstract][Full Text] [Related]
12. [Synergistic cytotoxicity effect of histone deacetylase inhibitor combined with paclitaxel on lung cancer cell lines and its mechanism].
Zhang D; Liu CT; Yu XD; Liu Y
Ai Zheng; 2009 Dec; 28(12):1270-6. PubMed ID: 19958621
[TBL] [Abstract][Full Text] [Related]
13. Subamolide A, a component isolated from Cinnamomum subavenium, induces apoptosis mediated by mitochondria-dependent, p53 and ERK1/2 pathways in human urothelial carcinoma cell line NTUB1.
Liu CH; Chen CY; Huang AM; Li JH
J Ethnopharmacol; 2011 Sep; 137(1):503-11. PubMed ID: 21708241
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
[TBL] [Abstract][Full Text] [Related]
15. Trichostatin A potentiates TRAIL-induced antitumor effects via inhibition of ERK/FOXM1 pathway in gastric cancer.
Li L; Fan B; Zhang LH; Xing XF; Cheng XJ; Wang XH; Guo T; Du H; Wen XZ; Ji JF
Tumour Biol; 2016 Aug; 37(8):10269-78. PubMed ID: 26831669
[TBL] [Abstract][Full Text] [Related]
16. Different effect of protein kinase B/Akt and extracellular signal-regulated kinase inhibition on trichostatin A-induced apoptosis in epithelial ovarian carcinoma cell lines.
Jang ER; Kim YJ; Myung SC; Kim W; Lee CS
Mol Cell Biochem; 2011 Jul; 353(1-2):1-11. PubMed ID: 21380726
[TBL] [Abstract][Full Text] [Related]
17. Effect of trichostatin A on Burkitt's lymphoma cells: Inhibition of EPS8 activity through Phospho-Erk1/2 pathway.
Sun P; Zhou X; He Y; Liu H; Wang Y; Chen Y; Li M; He Y; Li G; Li Y
Biochem Biophys Res Commun; 2018 Mar; 497(4):990-996. PubMed ID: 29462617
[TBL] [Abstract][Full Text] [Related]
18. New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.
Meneceur S; De Vos CE; Petzsch P; Köhrer K; Niegisch G; Hoffmann MJ
J Cell Mol Med; 2024 May; 28(9):e18342. PubMed ID: 38693852
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
Zhang X; Yashiro M; Ren J; Hirakawa K
Oncol Rep; 2006 Sep; 16(3):563-8. PubMed ID: 16865256
[TBL] [Abstract][Full Text] [Related]
20. Trichostatin A promotes esophageal squamous cell carcinoma cell migration and EMT through BRD4/ERK1/2-dependent pathway.
Liu D; Liu Y; Qi B; Gu C; Huo S; Zhao B
Cancer Med; 2021 Aug; 10(15):5235-5245. PubMed ID: 34160902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
